JP2010529994A5 - - Google Patents

Download PDF

Info

Publication number
JP2010529994A5
JP2010529994A5 JP2010512352A JP2010512352A JP2010529994A5 JP 2010529994 A5 JP2010529994 A5 JP 2010529994A5 JP 2010512352 A JP2010512352 A JP 2010512352A JP 2010512352 A JP2010512352 A JP 2010512352A JP 2010529994 A5 JP2010529994 A5 JP 2010529994A5
Authority
JP
Japan
Prior art keywords
compound
deuterium
hydrogen
independently
enantiomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010512352A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010529994A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/066730 external-priority patent/WO2008157240A1/en
Publication of JP2010529994A publication Critical patent/JP2010529994A/ja
Publication of JP2010529994A5 publication Critical patent/JP2010529994A5/ja
Pending legal-status Critical Current

Links

JP2010512352A 2007-06-13 2008-06-12 置換ピペラジン Pending JP2010529994A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94373107P 2007-06-13 2007-06-13
PCT/US2008/066730 WO2008157240A1 (en) 2007-06-13 2008-06-12 Substituted piperazines

Publications (2)

Publication Number Publication Date
JP2010529994A JP2010529994A (ja) 2010-09-02
JP2010529994A5 true JP2010529994A5 (enExample) 2011-07-28

Family

ID=39609397

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010512352A Pending JP2010529994A (ja) 2007-06-13 2008-06-12 置換ピペラジン

Country Status (9)

Country Link
US (2) US20080312247A1 (enExample)
EP (1) EP2155697B1 (enExample)
JP (1) JP2010529994A (enExample)
KR (1) KR20100047190A (enExample)
CN (1) CN101835761A (enExample)
AU (1) AU2008266124A1 (enExample)
CA (1) CA2690379A1 (enExample)
IL (1) IL202666A0 (enExample)
WO (1) WO2008157240A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010520291A (ja) * 2007-03-07 2010-06-10 コンサート ファーマシューティカルズ インコーポレイテッド 抗狭心症化合物としての重水素化ピペラジン誘導体
US20110053968A1 (en) * 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
KR20120082906A (ko) 2009-09-30 2012-07-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 자가포식현상-향상 유전자 생성물의 조절을 통한 자가포식현상의 조절 방법
CN101811941A (zh) * 2010-03-12 2010-08-25 重庆欣欣向荣精细化工有限公司 邻羟基苯基烷基醚的制备方法
CN102295622A (zh) 2010-06-25 2011-12-28 上海冠杰生物医药科技有限公司 一种雷诺嗪的制备方法
EP2524688B1 (en) * 2011-05-11 2013-05-01 ratiopharm GmbH Composition for modified release comprising ranolazine
EP2717860A4 (en) * 2011-06-08 2014-11-05 Sti Pharma Llc FORMULATION FROM A WATER SOLUBLE AND PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND WITH CONTROLLED ABSORPTION FOR ONLY DAILY APPLICATION
HRP20191860T1 (hr) 2013-03-13 2019-12-27 Forma Therapeutics, Inc. Derivati 2-hidroksi-1-{4-[(4-fenilfenil)karbonil]piperazin-1-il}etan-1-ona i srodni spojevi kao inhibitori sintaze masnih kiselina (fasn) za liječenje raka
US20160030426A1 (en) * 2013-03-14 2016-02-04 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP3049084A4 (en) * 2013-09-25 2017-03-15 Cortendo AB (publ) Novel functionalized 5-(phenoxymethyl)-1,3-dioxane analogs exhibitng cytochrome p450 inhibition
WO2015120110A2 (en) 2014-02-07 2015-08-13 Auspex Pharmaceuticals, Inc. Novel pharmaceutical formulations
WO2020092395A1 (en) 2018-10-29 2020-05-07 Forma Therapeutics, Inc. SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE
CN116251072B (zh) * 2023-03-14 2023-09-15 郑州大学第一附属医院 一种吲哚布芬片及其制备方法、用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6884429B2 (en) * 1997-09-05 2005-04-26 Isotechnika International Inc. Medical devices incorporating deuterated rapamycin for controlled delivery thereof
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
US6396062B1 (en) * 1999-12-03 2002-05-28 Cymer, Inc. Portable laser beam monitor
DK1104760T3 (da) * 1999-12-03 2003-06-30 Pfizer Prod Inc Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
EP1134290A3 (en) * 2000-03-14 2004-01-02 Pfizer Products Inc. Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
WO2006008753A1 (en) * 2004-07-19 2006-01-26 Unichem Laboratories Limited Crystalline and amorphous form of ranolazine and the process for manufacturing them
AU2006274037B2 (en) * 2005-07-26 2012-04-26 Takeda Gmbh Isotopically substituted pantoprazole
US20080033011A1 (en) * 2005-07-29 2008-02-07 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives
CN101273024A (zh) * 2005-07-29 2008-09-24 康瑟特制药公司 新颖苯并[d][1,3]-二氧杂环戊烯衍生物
US7598273B2 (en) * 2005-10-06 2009-10-06 Auspex Pharmaceuticals, Inc Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JP2010520291A (ja) * 2007-03-07 2010-06-10 コンサート ファーマシューティカルズ インコーポレイテッド 抗狭心症化合物としての重水素化ピペラジン誘導体

Similar Documents

Publication Publication Date Title
JP2010530897A5 (enExample)
JP2010095546A5 (enExample)
JP2013032389A5 (enExample)
JP2013505929A5 (enExample)
JP2014500861A5 (enExample)
JP2007302689A5 (enExample)
JP2012532883A5 (enExample)
JP2010536889A5 (enExample)
JP2013510885A5 (enExample)
JP2012144574A5 (enExample)
JP2006526031A5 (enExample)
JP2009535462A5 (enExample)
JP2012092103A5 (enExample)
JP2015501820A5 (enExample)
HRP20221304T1 (hr) Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
EP4245369A3 (en) Neuroactive steroids, compositions, and uses thereof
JP2010501534A5 (enExample)
JP2011121940A5 (ja) 発光素子
JP2010540477A5 (enExample)
WO2010132765A3 (en) Antibacterial aminoglycoside analogs
JP2010520214A5 (enExample)
JP2012254971A5 (ja) カルバゾール化合物
JP2010534246A5 (enExample)
ATE537136T1 (de) Neues verfahren zur herstellung von säurechloriden
JP2010507590A5 (enExample)